Link to replay:


Targovax CMD 1_Welcome

Targovax CMD 2_Melanoma

Targovax CMD 3_ONCOS-102 Development program

Targovax CMD 4_Immune Activation

Targovax CMD 5_Preclinical pipeline update

Targovax CMD 6_4Q update

Targovax CMD 7_Closing remarks

Targovax ASA invites investors, analysts and media to a Capital Markets Day on Thursday 18 February 2021

Based on the strong clinical data that are now generated on ONCOS-102, Targovax has a solid fundament to move into late stage clinical development. We also have a broader pipeline of preclinical assets that could create a broader horizon of opportunities in the future. The Capital Markets day will feature presentations updating the market on these aspects.

DATE               Thursday, February 18, 2021
TIME                2:30 PM CET
LOCATION       Virtual event – live streaming
REPLAY           Available after the event

The agenda will be as follows:

Agenda & speakers

2:30-2:40 PM Welcome Øystein Soug, CEO, Targovax
2:40-3:25 PM Anti-PD1 refractory melanoma Alexander N. Shoushtari, MD
3:25-3:45 PM ONCOS-102 development program Magnus Jäderberg, CMO, Targovax

5 minutes break

3:50-4:05 PM Immune activation Victor Levitsky, CSO, Targovax
4:05-4:15 PM Preclinical pipeline update Victor Levitsky, CSO, Targovax
4:15-4:25 PM 4Q update Torbjørn Furuseth, CFO, Targovax
4:25 PM Closing remarks Øystein Soug, CEO, Targovax

The presentations will be made available on the company´s website after the end of the meeting. Questions can be submitted through the webcast throughout the event.


Dr. Alexander Shoushtari is renowned expert in melanoma, with a research focus on uveal and mucosal melanomas. He is part of several immunotherapy trials at MSKCC and Dr. Alexander Shoushtari is the Principal Investigator on the ONCOS-102 phase I trial in CPI refractory advanced melanoma.